Home » Archive

Articles tagged with: vorinostat

Basic Research »

[14 Jan 2013 | No Comment | 8,415 views]
A new chance for Vorinostat?

September 29, 2011 (Stockholm, Sweden) — The largest randomized phase 3 study ever conducted in patients with advanced malignant pleural mesothelioma has failed; no survival benefit was seen with vorinostat (Zolinza, Merck & Co).

Sadly yes, out of 660 patients, there was no significant difference in median overall survival between the vorinostat and placebo groups.

The latest article from Dr. Barbone and colleagues sheds some light on possible reasons for the unsuccessful outcome of the trial.

Basic Research »

[30 May 2011 | No Comment | 1,385 views]
Immunogenic status of mesothelioma is affected by epigenetic drugs

Here is a paper analyzing the intriguing possibility that epigenetic drugs may increase the immunogenic profile of mesothelioma, thereby enhancing the ability of an immune response to target the tumor. 
HDAC inhibitors and demethylating agents open the chromatin into a conformation that facilitates transcription not only of tumor suppressors but also of tumor antigens, such as NY-ESO-1, MAGE-A1 and MAGE-A3.